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Clinical Implications of Complex
Pharmacokinetics for Daratumumab
Dose Regimen in Patients With
Relapsed/Refractory Multiple Myeloma
XS Xu1, X Yan1, T Puchalski2, S Lonial3, HM Lokhorst4, PM Voorhees5, T Plesner6,
K Liu1, I Khan1, R Jansson2, T Ahmadi2, JJ Perez Ruixo7, H Zhou2 and PL Clemens2
New therapeutic strategies are urgently needed to improve
clinical outcomes in patients with multiple myeloma (MM).
Daratumumab is a ﬁrst-in-class, CD38 human immunoglobulin
G1jmonoclonal antibody approved for treatment of relapsed or
refractory MM. Identiﬁcation of an appropriate dose regimen
for daratumumab is challenging due to its target-mediated drug
disposition, leading to time- and concentration-dependent phar-
macokinetics. We describe a thorough evaluation of the recom-
mended dose regimen for daratumumab in patients with
relapsed or refractory MM.
Daratumumab is a ﬁrst-in-class, CD38 human immunoglobulin
G1j (IgG1j) monoclonal antibody (mAb) that recently received
accelerated approval from the US Food and Drug Administration
(FDA) for use in patients with multiple myeloma (MM) who have
received 3 lines of treatment including a proteasome inhibitor
and an immunomodulatory drug, or who are double refractory to
these agents, and received conditional marketing authorization
from the European Medicines Agency for the treatment of adults
with relapsed and refractory MM.1 Daratumumab binds with high
afﬁnity to CD38, which is ubiquitously expressed on myeloma cells.
The antimyeloma activity of daratumumab is mediated through a
number of pathways.1
The phase I/II ﬁrst-in-human study of daratumumab,
GEN501, evaluated doses ranging from the minimal anticipated
biological effect level (0.005 mg/kg) to 24 mg/kg, administered
intravenously (i.v.). The maximum tolerated dose was not
reached.2 Over the range of evaluated doses, increases in area
under the curve were more than dose proportional; increasing
dose and repeated dosing led to decreased clearance, suggesting
target-mediated clearance.3 Therefore, a tapered dosing schedule
was established. Results from GEN501 showed encouraging efﬁ-
cacy and a favorable safety proﬁle with daratumumab monother-
apy in patients with heavily pretreated and refractory MM.2
However, pharmacokinetic analyses from GEN501 suggested
that the 8 mg/kg dose was lower than the trough threshold for tar-
get saturation.4 At the same time, efﬁcacy analyses of the 8 mg/kg
dose in the phase II SIRIUS study demonstrated a low overall
response rate (ORR).4 In contrast, daratumumab 16 mg/kg demon-
strated deep and durable responses while maintaining a favorable
safety proﬁle; therefore, daratumumab 16 mg/kg once weekly
(QW) for 8 weeks, every 2 weeks (Q2W) for 16 weeks, and every 4
weeks (Q4W) thereafter was established as the recommended dos-
ing schedule.4
Identiﬁcation of an appropriate dose and dosing schedule is
complex for daratumumab due to its target-mediated drug dispo-
sition (TMDD), which leads to time- and concentration-
dependent pharmacokinetics (PK).3 Additionally, concentrations
decrease over time as daratumumab is tapered from QW to
Q4W dosing. Therefore, it is important to determine whether
most patients can achieve efﬁcacious concentrations after the
QW 16 mg/kg dosing of daratumumab, and whether sufﬁcient
target saturation can be maintained during Q2W or Q4W dosing
to reduce the risk of disease progression.
We evaluated PK and efﬁcacy/safety data collected from GEN501
(N 5 104; ClinicalTrials.gov Identiﬁer: NCT00574288)2 and
SIRIUS (N 5 124; NCT01985126)4 to understand the clinical
implications of the complex PK on the daratumumab dose regimen.
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Details on patient eligibility, study designs for GEN501 and SIRIUS,
and population PK modeling are described in the Supplemental
Methods, Supplemental Table 1, and Supplemental Figures 1
and 2. We ﬁrst investigated the relationship between maximal
trough concentration (Ctrough,max) and the primary efﬁcacy endpoint,
ORR, to identify the effective induction concentration during the
intensive QW dosing. Among the tested exposure metrics, Ctrough,max
had the strongest correlation with ORR (Supplemental Table 2).
Second, analyses of time to progression (TTP) and duration of
response (DOR) were performed to determine whether there was
any association between decreases in daratumumab trough
concentrations (Ctrough,delta; the reduction in trough concentration
at the last dose from Ctrough,max) and the likelihood of disease pro-
gression. A PK model incorporating the drug-target binding was
developed5 and utilized to infer the pharmacodynamics of the
daratumumab-CD38 complex (i.e., target saturation over time). The
exposure-safety relationship between the peak concentration after
multiple doses (Cmax) and thrombocytopenia, anemia, neutropenia,
lymphopenia, or infections was assessed. Because the majority of
infusion-related reactions (IRRs) occurred during the ﬁrst dose, the
peak concentration after the ﬁrst dose (Cmax,1st) was used to evaluate
the relationship between exposure and IRRs.
ORR signiﬁcantly increased with Ctrough,max (P < 0.0001) via
a maximal effect (Emax) relationship (Figure 1a), where 90%
Emax on ORR (ECORR90 ) was achieved at 274 lg/mL. Limited
additional beneﬁt to ORR could be obtained when Ctrough,max
was above the ECORR90 . The Ctrough,max-ORR relationship was
virtually unchanged after adjusting for baseline disease-state varia-
bles (Supplemental Table 3). Although the observed ORR
appeared to be higher for the 8th quantile (Ctrough,max 5 900
lg/mL), the increase was not statistically signiﬁcant, as the conﬁ-
dence interval overlapped with the predicted ORR. Also, a hyper-
bolic Emax relationship was identiﬁed between daratumumab
concentration and target saturation (Figure 1b). The concentra-
tion estimated to provide 99% target saturation (ECTAR99 ) was
236 lg/mL, suggesting that a >99% target saturation at the end
of weekly dosing may be required to induce the clinical effect.
Simulations demonstrated that the 16-mg/kg dose was the lowest
tested i.v. dose at which the majority of patients (80%)
achieved Ctrough,max above EC
ORR
90 and EC
TAR
99 after QW dosing
(QW for 8 weeks). The 8-mg/kg QW dose produced Ctrough,max
above the ECORR90 and EC
TAR
99 in only 40% to 50% of patients.
Although the 24-mg/kg dose increased the number of patients
above the ECORR90 and EC
TAR
99 to 90%, the higher i.v. dose will
also produce much higher peak concentrations than the 16-mg/
kg dose and potentially compromise the safety proﬁle.
Figure 1 Exposure-response relationship between daratumumab
concentration and target saturation (a), and between ORR and predicted
Ctrough,max (b). Representative PK profile of daratumumab (c), including
boxplots for the target saturation profile of daratumumab at pre-infusion
time points for the patient population at the recommended dose and
schedule (d). Total and linear clearance vs. time for the daratumumab
16-mg/kg dose regimen (e). In Panel a, the centered curves and shaded
areas represent predicted target saturation and 95% CI, respectively. In
Panel b, the solid blue dots represent the proportion of responders
grouped by eight quantiles of Ctrough,max and plotted at the geometric mean
for each group. The bars represent the 95% CI for the proportion in each
group. The centered curves and shaded areas represent predicted ORR
values and 95% CIs of model-predicted response rate, respectively. The
horizontal boxplots represent the predicted (blue) and observed (green)
maximal trough concentration at daratumumab 16 mg/kg. In Panel c, the
green line indicates simulated population mean values and the pink shad-
ed area indicates the 95% prediction intervals. In Panels c–e, arrows indi-
cate the daratumumab 16-mg/kg dose regimen: QW for 8 weeks, Q2W for
16 weeks, and then Q4W thereafter. ORR, overall response rate; Ctrough,-
max, maximal trough concentration; PK, pharmacokinetic; CI, confidence
interval; QW, once weekly; Q2W, every 2 weeks; Q4W, every 4 weeks;
ECTAR99 , concentration estimated to provide 99% target saturation; EC
ORR
90 ,
concentration estimated to provide 90% maximal effect on ORR; DARA,
daratumumab; CI, confidence interval.
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There was no signiﬁcant relationship between Ctrough,delta and
either TTP (P 5 0.16) or DOR (P 5 0.44; Supplemental
Figure 3), suggesting that the decrease in concentration during
less frequent dosing intervals (Figure 1c) was unlikely to result in
shorter DOR or higher risk of disease progression. This is not
surprising, as the decrease in target saturation over time was mini-
mal in the majority of patients, with a median above 98% for
trough concentrations at 52 weeks (Figure 1d), despite the
decrease in daratumumab concentration over time. Further analy-
sis demonstrated that the total clearance of daratumumab
decreased over time (Figure 1e) and approached the nonspeciﬁc
clearance for IgGs by the end of the initial QW dosing period,
indicating that the saturation and depletion of CD38 is achieved
by the end of the QW dosing period (8 doses) and maintained
over time during the Q2W and Q4W dosing intervals.
Large-molecule mAbs for cancer treatment often exhibit
TMDD, resulting in higher clearance in the presence of the tar-
get.6,7 Following effective treatment for cancer, the amount of
target or receptors will most likely decrease rapidly due to killing
and depletion of tumor cells that carry the target receptors. This
may explain the time-dependent PK (i.e., decreasing clearance
over time) for daratumumab and some other recently developed
mAbs. The decrease in clearance over time for these mAbs may
require a more frequent dosing at the beginning of the treatment
to overcome the initially higher clearance of the drug, but a less
frequent dosing at later times to maintain the target saturation.
Therefore, QW dosing for daratumumab at the beginning of
treatment helped overcome the high initial, target-mediated clear-
ance and rapidly established efﬁcacious concentrations. Thereaf-
ter, although the concentration of daratumumab tended to
decrease following the Q2W and Q4W dosing until reaching
steady state, the concentration levels during less frequent dosing
intervals were sufﬁcient to maintain target saturation, thus reduc-
ing the risk of disease progression.
There was no apparent relationship within the investigated
concentration range between Cmax,1st and IRRs, or between Cmax
and thrombocytopenia, anemia, neutropenia, and lymphopenia
(Figure 2a,b). Although the overall event rate of infection
appeared to increase numerically with drug exposure, this trend
was not observed for grade 3 infections. Incidence of grade 3
adverse events was slightly numerically lower in patients with
higher daratumumab exposure quartiles than in patients with
lower exposure. These observations are consistent with the clini-
cal data, in which no dose-related safety signal was observed.2,4
The safety proﬁle of daratumumab doses >16 mg/kg has not
been investigated beyond three patients treated with 24 mg/kg in
the GEN501 study.
Taken together, daratumumab exhibits complex time- and
concentration-dependent PK. The drug exposure was strongly
correlated with efﬁcacy, but not with the safety endpoints ana-
lyzed. The target effective trough concentration (ECORR90 ) and the
required target saturation were identiﬁed to be 274 lg/mL and
>99%, respectively, at the end of QW dosing. The currently rec-
ommended dose regimen of daratumumab (16 mg/kg; QW for
8 weeks, Q2W for 16 weeks, and Q4W thereafter) provides a bal-
anced beneﬁt–risk proﬁle for i.v. administration in the relapsed
or refractory MM patient population (i.e., 80% of patients
could achieve the identiﬁed effective concentration with an
acceptable safety proﬁle). Further optimization of the PK and
dose through development of new formulations and routes of
delivery (e.g., subcutaneous administration) may allow more
patients to attain the identiﬁed effective trough concentration
Figure 2 Exposure-response relationship between adverse events and predicted Cmax (a,b). Panels a,b show the rate of adverse events of interest by
exposure quartile. Cmax,1st was used as the exposure measure for analyses of IRRs. Cmax was used as the exposure measure for analyses of other
adverse events. The quartiles for Cmax,1st were: 1st quartile (134 lg/mL), 2nd quartile (134–245 lg/mL), 3rd quartile (245–310 lg/mL), and 4th quar-
tile (310–470 lg/mL). The quartiles for Cmax are: 1st quartile (270 lg/mL), 2nd quartile (270–511 lg/mL), 3rd quartile (511–907 lg/mL), and 4th
quartile (907–1,840 lg/mL). IRR, infusion-related reaction; Cmax, overall maximum concentration; Cmax,1st, peak concentration after the first infusion.
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without a signiﬁcant increase in peak concentrations, therefore
further improving the clinical beneﬁt-risk proﬁle for daratumu-
mab. Lastly, due to the depletion of the target on tumor cells
over time following treatments, mAb therapies with TMDD may
display decreasing clearance over time. Therefore, after an inten-
sive induction period to overcome the initially higher clearance,
less frequent dosing may be sufﬁcient to maintain target satura-
tion, thus reducing the risk of disease progression.
Additional Supporting Information may be found in the online version of
this article.
ACKNOWLEDGMENTS
This study was sponsored by Janssen Research & Development, LLC.
The authors wish to thank the patients participating in this study and
their families, as well as the global network of investigators, research
nurses, study coordinators, and operations staff. Medical writing and
editorial support were provided by Erica S. Chevalier-Larsen of MedErgy
(Yardley, PA, USA), and were funded by Janssen Global Services, LLC.
AUTHOR CONTRIBUTIONS
X.S.X. contributed to the scientific literature search, data acquisition,
and interpretation and analysis. X.Y. contributed to data acquisition and
interpretation and analysis. T. Puchalski contributed to data acquisition
and interpretation and analysis. S.L. contributed to the accrual and treat-
ment of patients and data acquisition. T. Plesner and H.M.L. contributed
to the accrual and treatment of patients and data acquisition. P.M.V. con-
tributed to the accrual and treatment of patients and data acquisition.
K.L. contributed to data interpretation and analysis. I.K. contributed to
data acquisition and interpretation and analysis. R.J. contributed to data
interpretation and analysis. T.A. contributed to data acquisition and inter-
pretation and analysis. J.J.P.R. contributed to interpretation and analy-
sis. H.Z. contributed to interpretation and analysis. P.L.C. contributed to
data acquisition and interpretation and analysis. All authors drafted and
reviewed the article, approved the final version, and decided to publish
this report; all authors vouch for data accuracy and completeness.
CONFLICT OF INTEREST/DISCLOSURE
X.S.X., X.Y., T. Puchalski, K.L., I.K., R.J., T.A., J.J.P.R., H.Z., and P.L.C.
are employees of Janssen Research & Development, LLC. X.S.X., X.Y., T.
Puchalski, R.J., J.J.P.R., H.Z., and P.L.C. own stock in Johnson & John-
son, and J.J.P.R. owns stock in Amgen. S.L. reports consultancy and
research funding from Millennium, Novartis, Bristol-Myers Squibb, Onyx,
Celgene, and Janssen. H.M.L. reports honoraria from Amgen and hono-
raria and research funding from Genmab and Janssen. P.M.V. reports
consultancy from Janssen, Millennium Pharmaceuticals: A Takeda Oncol-
ogy Company, Celgene, Novartis, Array BioPharma, and Oncopeptides;
and research funding from Janssen, Celgene, GlaxoSmithKline, Onyx
Pharmaceuticals, and Oncopeptides. T. Plesner reports research funding
from Janssen and has served on advisory boards for Janssen.
VC 2017 The Authors Clinical Pharmacology & Therapeutics published by
Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacol-
ogy and Therapeutics.
This is an open access article under the terms of the Creative Commons
Attribution-NonCommercial-NoDerivs License, which permits use and distri-
bution in any medium, provided the original work is properly cited, the use
is non-commercial and no modifications or adaptations are made.
1. McKeage, K. & Lyseng-Williamson, K.A. Daratumumab in multiple
myeloma: a guide to its use as monotherapy in the EU. Drugs Ther.
Perspect. 32, 463–469 (2016).
2. Lokhorst, H.M. et al. Targeting CD38 with daratumumab
monotherapy in multiple myeloma. N. Engl. J. Med. 373, 1207–
1219 (2015).
3. Clemens, P.L. et al. Pharmacokinetics of daratumumab following
intravenous infusion in relapsed or refractory multiple myeloma
(MM) after prior proteasome inhibitor (PI) and immunomodulatory
drug (IMiD) treatment. Clin. Lymphoma Myeloma Leuk. 15, e269–
e270 (2015).
4. Lonial, S. et al. Daratumumab monotherapy in patients with treatment-
refractory multiple myeloma (SIRIUS): an open-label, randomised,
phase 2 trial. Lancet 387, 1551–1560 (2016).
5. Yan, X. et al. Target-mediated drug disposition of daratumumab
following intravenous infusion in relapsed or refractory multiple
myeloma after prior proteasome inhibitors and immunomodulatory
drugs: a population pharmacokinetic analysis. Blood 126, 4222
(2015).
6. Alinari, L. et al. Alemtuzumab (Campath-1H) in the treatment of chronic
lymphocytic leukemia. Oncogene 26, 3644–3653 (2007).
7. Gibiansky, E. et al. Population pharmacokinetics of obinutuzumab
(GA101) in chronic lymphocytic leukemia (CLL) and non-Hodgkin’s
lymphoma and exposure-response in CLL. CPT Pharmacometrics Syst.
Pharmacol. 3, 1–11 (2014).
DEVELOPMENT
724 VOLUME 101 NUMBER 6 | JUNE 2017 | www.cpt-journal.com
